Understanding Molecular Testing In Egfr Mutant Driven Nsclc
Let's dive into the details surrounding Molecular Testing In Egfr Mutant Driven Nsclc. Julia Rotow, MD, Dana-Farber Cancer Institute, Boston, MA, discusses
Key Takeaways about Molecular Testing In Egfr Mutant Driven Nsclc
- All metastatic
- Panelists Mark Socinski, MD; Vali Papadimitrakopoulou, MD; Tracey Evans, MD; Alexander Drilon, MD; and Jared Weiss, MD, ...
- John Heymach, MD, discusses repeat liquid or tissue biopsies,
- Learn more about
- Current recommendations for
Detailed Analysis of Molecular Testing In Egfr Mutant Driven Nsclc
Lynette M. Sholl, MD, and Geoffrey R. Oxnard, MD, discuss A key opinion leader discusses the importance of For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Recommendations for
That wraps up our extensive overview of Molecular Testing In Egfr Mutant Driven Nsclc.